93.79
1.41 (1.53%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Disc Medicine, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.00 |
|
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company’s preclinical programs include DISC-0998. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 10.65% |
| 机构持股比例 | 99.13% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Atlas Venture Life Science Advisors, Llc | 30 Sep 2025 | 2,142,617 |
| Frazier Life Sciences Management, L.P. | 30 Sep 2025 | 1,438,534 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 153.00 (Cantor Fitzgerald, 63.13%) | 购买 |
| 中 | 114.50 (22.08%) | |
| 低 | 108.00 (Raymond James, 15.15%) | 购买 |
| 平均值 | 120.83 (28.83%) | |
| 总计 | 6 购买 | |
| 平均价格@调整类型 | 87.31 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Truist Securities | 10 Nov 2025 | 114.00 (21.55%) | 购买 | 83.58 |
| Stifel | 03 Nov 2025 | 125.00 (33.28%) | 购买 | 84.69 |
| Morgan Stanley | 30 Oct 2025 | 115.00 (22.61%) | 购买 | 85.75 |
| Cantor Fitzgerald | 17 Oct 2025 | 153.00 (63.13%) | 购买 | 89.94 |
| Raymond James | 17 Oct 2025 | 108.00 (15.15%) | 购买 | 89.94 |
| Wedbush | 17 Oct 2025 | 110.00 (17.28%) | 购买 | 89.94 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合